Abstract
A single-chain Fv antibody fragment specific for the tumor-associated Ep-CAM molecule was isolated from a semisynthetic phage display library and converted into an intact, fully human IgG1 monoclonal antibody (huMab). The purified huMab had an affinity of 5 nM and effectively mediated tumor cell killing in in vitro and in vivo assays. These experiments show that nonimmunized phage antibody display libraries can be used to obtain high-affinity, functional, and clinically applicable huMabs directed against a tumor-associated antigen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shawler, D.L., Bartholomew, R.M., Smith, L.M. & Dillman, R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135, 1530–1535 (1985).
Miller, R.A., Oseroff, A.R., Stratte, P.T. & Levy, R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62, 988–995 ( 1983).
Hakimi, J. et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. 147, 1352–1359 (1991).
Stephens, S. et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85 , 668–674 (1995).
Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323– 327 (1988).
Junghans, R.P. et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50, 1495–1502 (1990).
Vaughan, T.J., Osbourn, J.K. & Tempest, P.R. Human antibodies by design. Nat. Biotechnol . 16, 535–539 ( 1998).
Khazaeli, M.B. et al. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma4) monoclonal antibody in humans. Cancer Res . 51, 5461–5466 ( 1989).
Elliot, M.J. et al. Repeated therapy with monoclonal antibody to tumor necrosis factor alfa (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1127 (1994).
Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 , 522–525 (1986).
Foote, J. & Winter, G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224, 487–499 (1992).
McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825– 2833 (1998).
Pegram, M.D. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 Her2/neu monoclonal antibody plus cisplatin in patients with Her2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659– 2671 (1998).
Vincenti, F. et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl. J. Med. 338, 161–165 (1998).
Bruggeman, M. & Neuberger, M.S. Strategies for expressing human antibody repertoires in transgenic mice. Immunol. Today 17, 391–397 (1996).
Mendez, M.J. et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146–156 (1997).
Winter G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol . 12, 433–455 ( 1994).
Burton, D.R. & Barbas III, C.F. Human antibodies from combinatorial libraries. Adv. Immunol. 57, 191–280 (1994).
De Kruif, J., Terstappen, L., Boel, E. & Logtenberg, T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA 92, 3938–3942 (1995).
Riethmuller, G. et al. 1994. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes = C colorectal carcinoma. Lancet 343, 1177–1183 (1994).
De Kruif, J., Boel, E.Z. & Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. 248, 97– 105 (1995).
Gottlinger, H.G., Funke, I., Johnson, J., Gokel, J.M. & Riethmuller, G. The epithelial cell surface antigen CO17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer 38, 47–53 ( 1986).
Momberg, F., Moldenhauer, G., Hammerling, G.J. & Moller, P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res . 47, 2883–2891 ( 1987).
Thampoe, I.J., Ng, J.S.C. & Lloyd, K.O. Biochemical analysis of a human epithelial surface antigen: differential cell expression and processing. Arch. Biochem. Biophys . 267, 342–352 ( 1988).
Simon, B. et al. Epithelial glycoprotein is a member of a family of epithelial surface antigens homologous to nidogen, a matrix adhesion protein. Proc. Natl. Acad. Sci. USA 87, 2755–2759 ( 1990).
Litvinov, S.V., Velders, M.P., Bakker, H.A.M., Fleuren, G.J. & Warnaar, S.O. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125, 437–446 (1994).
Steplewski, Z. et al. Biological activity of human-mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 85, 4852–4856 ( 1988).
Pak, K.Y. et al. 1991. Evaluation of the 323/A3 monoclonal antibody and the use of technetium-99m-labeled 323/A3 Fab' for the detection of panadenocarcinoma. Int. J. Rad. Appl. Instrum. 18, 483–497 (1991).
Velders, M.P. et al. The role of antibody affinity in tumor immunotherapy evaluated in in-vivo models for minimal residual disease. J. Immunother. 19, 245–256 (1996).
Heijnen, I.A.F.M. & van de Winkel, J.G.J. Human IgG Fc receptors. Int. Rev. Immunol. 16, 29–56 ( 1997).
Valerius, T. et al. Involvement of the high affinity receptor for IgG (FcgammaRI:CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82, 931–939 ( 1993).
Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A. & Mueller, B.M. Therapeutic potential of chimeric and murine anti-EGF receptor antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. 37, 343– 349 (1993).
Nishimura, Y. et al. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. Cancer Res. 47, 999–1005 (1987).
Liu, A.Y. et al. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA. 84, 3439– 3443 (1987).
Takahashi, H., Nakada, T., Nakaki, M. & Wands, J.R. Inhibition of hepatic metastases of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody. Gastroenterology. 108, 172–182 (1995).
Walker, M.R., Lund, J., Thompson, K.M. & Jefferis, R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem. J. 259, 347–353 (1989).
LoBuglio, A.F. et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA 86, 4220–4224 (1989).
Balzar, M. et al. Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Mol. Cell. Biol. 18, 4833–4843 (1998).
De Leij, L., Helfrich, W., Stein, R. & Mattes, M.J. SCLC Cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int. J. Cancer suppl. 8, 60–63 (1994).
Meerman, H.J. & Georgiou, G. Construction and characterization of a set of E.coli strains deficient in all known loci affecting the proteolytic stability of secreted recombinant proteins. Bio/Technology 12, 1107–1109 ( 1994).
De Kruif, J., Storm, G., van Bloois, L. & Logtenberg, T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett . 199, 232–236 ( 1996).
Hale, J.E. Irreversible, oriented immobilization of antibodies to cobalt-iminodiacetate resin for use as immunoaffinity media. Anal. Biochem. 231, 46–49 (1995).
Lankhof, H. PhD thesis. University of Utrecht. The Netherlands ( 1996).
Karlsson, R., Michaelson, A. & Mattson, L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods . 198, 129–137 ( 1991).
Van Strijp, J.A.G., van Kessel, K.P.M., van der Tol, M.E. & Verhoef, J. Complement-mediated phagocytosis of herpes simplex virus by human granulocytes: binding or ingestion. J. Clin. Invest. 84, 107–112 (1989).
Acknowledgements
The authors would like to thank T. Furebring and A. Marguart for advice on affinity measurements on the BIAcore and N. Barker for critically reading the manuscript. I.A.F.M. Heijnen is supported by grant 13104-CT97-2216 from the European Community.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huls, G., Heijnen, I., Cuomo, M. et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17, 276–281 (1999). https://doi.org/10.1038/7023
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/7023
This article is cited by
-
Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models
Nature Communications (2023)
-
A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM
Journal of Molecular Evolution (2015)
-
Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)
Journal of Hematology & Oncology (2008)
-
Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer
Journal of Molecular Medicine (2007)
-
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Nature Reviews Drug Discovery (2003)